Safety and Immunogenicity of a Human Hookworm Candidate Vaccine With Different Doses of a Novel Adjuvant

Inclusion Criteria: * Males or females between 18 and 45 years, inclusive. * Good general health as determined by means of the screening procedure. * Available for the duration of the trial (16 months). * Willingness to participate in the study as evidenced by signing the informed consent document. Exclusion Criteria: * Pregnancy as determined by a positive urine β-hCG (if female). * Participant unwilling to use reliable contraception methods up until one month following the third immunization (if female). * Currently lactating and breast-feeding (if female). * Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, rheumatologic, autoimmune, diabetes, or renal disease by history, physical examination, and/or laboratory studies. * Known or suspected immunodeficiency. * Laboratory evidence of liver disease (alanine aminotransferase \[ALT\] greater than 1.25-times the upper reference limit). * Laboratory evidence of renal disease (serum creatinine greater than 1.25-times the upper reference limit, or more than trace protein or blood on urine dipstick testing). * Laboratory evidence of hematologic disease (hemoglobin \<12.5 g/dl \[females\] or \<13.5 g/dl \[males\]; absolute leukocyte count \<3500/mm-cubed or \>10.5 x 103/mm-cubed; absolute neutrophil count \[ANC\] \<2000/ mm-cubed; absolute lymphocyte count \<1100/mm-cubed; or platelet count \<140,000/mm-cubed). * Laboratory evidence of a coagulopathy (PTT or PT INR greater than 1.1-times the upper refere…